Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 14/20 | 0.56 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | F7 | P08709 | 1/20 | 0.39 |
| ▸ | F3 | P13726 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | GUSB | P08236 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3274871 | 0.85 | HRH4 (0.56) | HRH4GRIN1KDM4EGRIN2DGRIN3B | |
| SCHEMBL29062685 | 0.84 | HRH4 (0.55) | HRH4GRIN1KDM4EGRIN2DGRIN3B | |
| SCHEMBL30305564 | 0.76 | HRH4 (0.57) | HRH4GRIN1KDM4EALDH1A1GRIN2B | |
| SCHEMBL4396474 | 0.76 | ALOX15 (0.58) | HRH4KDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL30457751 | 0.76 | ALOX15 (0.58) | HRH4KDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL24740103 | 0.76 | ALOX15 (0.58) | HRH4 | |
| SCHEMBL24019966 | 0.76 | ALOX15 (0.58) | HRH4ALDH1A1GAAGUSB | |
| SCHEMBL9756096 | 0.74 | HRH4 (0.46) | HRH4GRIN1KDM4EGRIN2DGRIN3B | |
| SCHEMBL6141629 | 0.74 | HRH4 (0.76) | HRH4 | |
| SCHEMBL604650 | 0.73 | HRH4 (1.00) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111050765-B | Spiro compounds and methods of making and using the same | H.隆德贝克有限公司 | 2024-01-02 | — | — | CN | disclosed |
| EP-3675847-B1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H LUNDBECK AS (DK) | 2023-07-12 | — | — | EP | disclosed |
| EP-3675847-B1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H LUNDBECK AS (DK) | 2023-07-12 | — | — | EP | disclosed |
| US-11142526-B2 | Spirocycle compounds and methods of making and using same | H. LUNDBECK A/S (DK) | 2021-10-12 | — | — | US | disclosed |
| US-11142526-B2 | Spirocycle compounds and methods of making and using same | H. LUNDBECK A/S (DK) | 2021-10-12 | — | — | US | disclosed |
| US-20200255427-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2020-08-13 | — | — | US | disclosed |
| US-20200255427-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2020-08-13 | — | — | US | disclosed |
| EP-3675847-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | Lundbeck La Jolla Research Center, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| CN-111050765-A | Spiro compounds and methods of making and using the same | 隆德贝克拉荷亚研究中心有限公司 | 2020-04-21 | — | — | CN | disclosed |
| WO-2019046318-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| US-20100087479-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-08 | — | — | US | disclosed |
| US-7615563-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-10 | — | — | US | disclosed |
| US-7615563-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-10 | — | — | US | disclosed |
| US-7615563-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-10 | — | — | US | disclosed |
| EP-1673357-A2 | HETEROARYLAMINOSULFONYLPHENYL DERIVATIVES FOR USE AS SODIUM OR CALCIUM CHANNEL BLOCKERS IN THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-02-02 | — | — | US | disclosed |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-02-02 | — | — | US | disclosed |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-02-02 | — | — | US | disclosed |
| US-20050137190-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2005-06-23 | — | — | US | disclosed |
| WO-2005013914-A2 | HETEROARYLAMINOSULFONYLPHENYL DERIVATIVES FOR USE AS SODIUM OR CALCIUM CHANNEL BLOCKERS IN THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255427-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | OPRL1, MGLL, OPRK1 | HRH4 4812/4885GRIN1 315/4885KDM4E 3640/4885 |
| US-20100087479-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | SCNN1G, KCNN3, KCNN2 | HRH4 1939/4885GRIN1 177/4885KDM4E 2385/4885 |
| US-20050137190-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | SCNN1G, KCNN3, KCNN2 | HRH4 1939/4885GRIN1 177/4885KDM4E 2385/4885 |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | SCNN1G, KCNN3, KCNN2 | HRH4 1939/4885GRIN1 177/4885KDM4E 2385/4885 |
| US-11142526-B2 | Spirocycle compounds and methods of making and using same | OPRL1, MGLL, OPRK1 | HRH4 4812/4885GRIN1 315/4885KDM4E 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.